These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 19943881

  • 1. Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial.
    Anderson JA, Hirsh J, Yusuf S, Johnston M, Afzal R, Mehta SR, Fox KA, Budaj A, Eikelboom JW.
    J Thromb Haemost; 2010 Feb; 8(2):243-9. PubMed ID: 19943881
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
    Mehta SR, Granger CB, Eikelboom JW, Bassand JP, Wallentin L, Faxon DP, Peters RJ, Budaj A, Afzal R, Chrolavicius S, Fox KA, Yusuf S.
    J Am Coll Cardiol; 2007 Oct 30; 50(18):1742-51. PubMed ID: 17964037
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5).
    Ross Terres JA, Lozano-Ortega G, Kendall R, Sculpher MJ.
    BMC Cardiovasc Disord; 2015 Dec 29; 15():180. PubMed ID: 26715178
    [Abstract] [Full Text] [Related]

  • 7. Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6.
    Karthikeyan G, Mehta SR, Eikelboom JW.
    Expert Rev Cardiovasc Ther; 2009 Mar 29; 7(3):241-9. PubMed ID: 19296760
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
    Gerotziafas GT, Depasse F, Chakroun T, Van Dreden P, Samama MM, Elalamy I.
    Blood Coagul Fibrinolysis; 2004 Mar 29; 15(2):149-56. PubMed ID: 15091002
    [Abstract] [Full Text] [Related]

  • 9. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes.
    Fox KA, Bassand JP, Mehta SR, Wallentin L, Theroux P, Piegas LS, Valentin V, Moccetti T, Chrolavicius S, Afzal R, Yusuf S, OASIS 5 Investigators.
    Ann Intern Med; 2007 Sep 04; 147(5):304-10. PubMed ID: 17785485
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk.
    Joyner CD, Peters RJ, Afzal R, Chrolavicius S, Mehta SR, Fox KA, Granger CB, Franzosi MG, Flather M, Budaj A, Bassand JP, Yusuf S.
    Am Heart J; 2009 Mar 04; 157(3):502-8. PubMed ID: 19249421
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile.
    Gerotziafas GT, Chakroun T, Samama MM, Elalamy I.
    Thromb Haemost; 2004 Dec 04; 92(6):1296-302. PubMed ID: 15583737
    [Abstract] [Full Text] [Related]

  • 14. Fondaparinux or enoxaparin: a comparative study of postoperative bleeding in coronary artery bypass grafting surgery.
    Landenhed M, Johansson M, Erlinge D, Olsson ML, Bjursten H.
    Scand Cardiovasc J; 2010 Apr 04; 44(2):100-6. PubMed ID: 19961287
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
    MICHELANGELO OASIS 5 Steering Committee, Mehta SR, Yusuf S, Granger CB, Wallentin L, Peters RJ, Bassand JP, Budaj A, Joyner C, Chrolavicius S, Fox KA.
    Am Heart J; 2005 Dec 04; 150(6):1107. PubMed ID: 16338245
    [Abstract] [Full Text] [Related]

  • 18. Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010.
    Puymirat E, Schiele F, Ennezat PV, Coste P, Collet JP, Bonnefoy-Cudraz E, Roul G, Richard P, Simon T, Danchin N.
    Eur Heart J Acute Cardiovasc Care; 2015 Jun 04; 4(3):211-9. PubMed ID: 25075006
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.